SSRIs and persistent pulmonary hypertension of the newborn: Observational evidence suggests a link, but causation is yet to be established

BMJ (Online)

Volumn 344, Issue 7842, 2012, Pages

  Koren, Gideon ^a   Nordeng, Hedvig ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ATTRIBUTABLE RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONGENITAL HEART MALFORMATION; DEPRESSION; DIAGNOSTIC ACCURACY; DIAPHRAGM HERNIA; DISEASE ASSOCIATION; DISEASE MODEL; DRUG USE; EDITORIAL; FETUS RISK; HUMAN; MECONIUM ASPIRATION; METHODOLOGY; MORTALITY; NEWBORN CARE; NONHUMAN; PATHOPHYSIOLOGY; PERINATAL ASPHYXIA; PERINATAL DRUG EXPOSURE; PERSISTENT PULMONARY HYPERTENSION; PHARMACOEPIDEMIOLOGY; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK ASSESSMENT; SEPSIS; STATISTICAL ANALYSIS; TERATOGENESIS; THIRD TRIMESTER PREGNANCY; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; FETUS; HEALTH SURVEY; NOTE; PREGNANCY; PREGNANCY COMPLICATION;

DEPRESSIVE DISORDER; FEMALE; FETUS; HUMANS; HYPERTENSION, PULMONARY; POPULATION SURVEILLANCE; PREGNANCY; PREGNANCY COMPLICATIONS; SEROTONIN UPTAKE INHIBITORS;

EID: 84859003571     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d7642     Document Type: Editorial

References (11)

1. Konduri GG, Kim UO. Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatr Clin North Am 2009;56:579-600.
2. Ostrea EM, Villanueva-Uy ET, Natarajan G, Uy HG. Persistent pulmonary hypertension of the newborn: pathogenesis, etiology, and management. Paediatr Drugs 2006;8:179-88. (Pubitemid 43927187)
3. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:579-87. (Pubitemid 43209105)
4. Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010;40:1723-33.
5. Andrade SE, McPhillips H, Loren D, Raebel MA, Lane K, Livingston J, et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2009;18:246-52.
6. Wichman CL, Moore KM, Lang TR, St Sauver JL, Heise RH Jr, Watson WJ. Congenital heart disease associated with SSRI during pregnancy. Mayo Clin Proc 2009;84:23-7.
7. Wilson KL, Zelig CM, Harvey JP, Cunningham BS, Dolinsky BM, Napolitano PG. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol 2011;28:19-24.
8. Kieler H, Artama M, Engeland A, Ericsson Ö, Furu K, Gissler M, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from five Nordic countries. BMJ 2012;344:d8012.
9. Belik J. Fetal and neonatal effects of maternal drug treatment for depression. Semin Perinatol 2008;32:350-4.
10. Källén B, Nilsson E, Olausson PO. Antidepressant use during pregnancy: comparison of data obtained from a prescription register and from antenatal care records. Eur J Clin Pharmacol 2011;67:839-45.
11. Shepard TH. Proof of human teratogenicity. Teratology 1994;50:97-8.